BSTG 2.27
Going to be a big week for this one. Premarket news and financials Thurs, insider buying, 13.1 mil float, estimated 1.5 billion dollar market when product approved... this is a definite diamond in the rough, chart is screaming for a breakout and I have been in this long enough that it will happen... for those looking for 25% gain this isn't even a doubt, but if this isn't trading between $4-5 by Friday, I will never post a speculative play on this board again... just want to pass the word, this company has a distinctive pattern of trading if you do some DD... here is a link that just came out this morning, it is well written... ~ GL

http://seekingalpha.com/instablog/175233-spencer-osborne/4878872-biostage-cellframe-technology-drive-portfolio-profits

BSTG $2.50 Hey, anybody watching this stock? 13.1 mil float, insider buying, $8 pt, replacement esophagus company, 1.5 billion dollar market if approved, large animal study results to be released pre market next Thurs.. small animal study 6 mos ago sent this stock up over 300%, formally HART, recent name change, no dilution, short interest is 6%, volume just increased 4x today!! Chart is booming... thought I would pass it on to anyone interested, don't see this one going backwards anytime soon, management seems to be doing everything right.. gl

IMNP 1.80 Stock is starting to run! Analyst upgrade to a "BUY" this week, volume has almost doubled by before noon on a Friday! Company has a lot of transformational news on the books.. Here is a quote from the ceo:
"The main near term catalysts in 2015 are the partnering of Amiket and phase 2 clinical data for Bertilimumab in Bullous Pemphigoid. Additional catalysts include but are not limited to orphan drug designation for Bertilimumab in Bullous Pemphigoid, First patient enrolled in the BP trial, First Patient enrolled in the Ulcerative Colitis phase 2 trial, potential data from pre-clinical and clinical investigator sponsored studies in additional indications for Bertilimumab, partnering of other small molecule pipeline drugs and of the NanomAb platform ADC candidates."

Float is super low and insider buying and shelf offering at $2.50 back in Nov!!!!!

GL seems to be an over looked diamond. Chart looking sweet!

imnp $1.80 Augusta, you mentioned you look for 8x34 crosses or ones that are very close, here is a gem for you. sitting 20% off its 52 week low, 18.7 mil float, 3 transformational catalysts due out at anytime, public offering and insider buying in Nov 14 @ $2.50, price target $8.50 median, and it's about to do the 8x34 cross!! It's been described as a sleeper on the street, and is going to explode soon imo.. check it out. ~ GL

Looks like the seeking alpha article is right... here's a small piece of a ton of transactions like the article said...


Godin, André
O 2375228 2013-12-03 2013-12-07 Direct Ownership :
10 - Acquisition or disposition in the public market +10,000 1.2500 USD 2018-12-03 Common Shares +10,000



A 2375228 2013-12-03 2013-12-09 Direct Ownership :
15 - Acquisition or disposition under a prospectus +10,000 2018-12-03 Common Shares +10,000



A ' 2375228 2013-12-03 2013-12-10 Direct Ownership :
15 - Acquisition or disposition under a prospectus +10,000 10,000 1.5000 USD 2018-12-03 Common Shares +10,000 10,000


Go to the SEDI link like you posted.
Click "View Summary Reports"
Click "insider transaction detail"
On first drop down click "Issuer name"
Then type in "Acasti"
Keep the next drop down box "Starts with"
Scroll down and hit select all for each option showing and hit "Search"
Select "View" on the next page
Happy reading!!! Looks like boat loads were acquired @ $1.25 just like seeking alpha said... should be a good month for us if the news is good!

NBY$1.02 Any takers NBY will climb another 30% to $1.30 within the next week? Anyone? I will just throw it out there based on the chart, not the fact that insiders bought the last 2 months, financials in a week, and topline data coming out from their phase 2 study Aug 15th..... so based on the chart alone, anyone want to wager this goes up 30% by next Friday to $1.30?

NBY $1 NBY is on fire with volume increasing. Already up 7% in two days. Big catalyst for the company 15th Aug, 39 mil float, insider buying May and June, chart on the uptick, price target $2.38.... just throwing this one out there for everyone to check out. Financials next week and if you read there shareholders letter from July 10th, the ceo mentions how they already have 2 fda approved products on the market! May be a clue for positive financials report coming... gl

http://finance.yahoo.com/news/letter-novabay-shareholders-223700386.html

NBY .95 This is the ground floor everyone. Gearing up for the $1 breakaway. Big news early August! $2.38 price target.

NBY .92 If you are looking for a very near term 10-15% check out NBY. Float 39mil, price target 2.38, near term catalyst Aug 8 financials and Aug 15th topline results for their eye wash solution for pink eye! Chart looks excellent and volume is starting to rise.

http://finance.yahoo.com/news/letter-novabay-shareholders-223700386.html

GL

I am going to go on a limb today and say we hear a decision by the end of the day, or Monday... just my opinion. We should also see a share spike at the end of the day because the we have been added to the Russell Microcap index and it will be reconstituted at the close of business today... I am hoping they will buy a dump truck load and get this party started... such a low float, I think things are about to get crazy! ~ GL

This is all you need to know about NAVB. They just got non-dilutive financing for the future and is expecting 5-6 million in revenue for 2014 as compared to $614,000 from last. That's a big deal for the quarters to come ~ GL

So what: For the quarter, Navidea reported revenue of $535,000, consisting of $343,000 from its FDA-approved lymphatic mapping agent Lymphoseek, up from $144,000 in sales in the sequential third quarter. Net loss, however, jumped considerably to $13.1 million from $7 million in the year-ago period. This translated into a net loss of $0.10 per share, $0.01 per share worse than analysts had predicted. Looking ahead, Navidea anticipates $5 million-$6 million in Lymphoseek revenue in fiscal 2014 compared to $614,000 in fiscal 2013.

Navidea also announced that it had closed on a $30 million five-year senior secured term loan with Oxford Finance, which will help with the commercialization and education of Lymphoseek.

Now what: You might be scratching your head and thinking to yourself, "Didn't Navidea miss its EPS loss estimate? Why are shares up?" The reason is a combination of rapid sequential growth in Lymphoseek from the third quarter, as well as the recently closed non-dilutive financing, which will allow it to aggressively market Lymphoseek. What investors should have their eyes on here is the mid-June PDUFA date to expand Lymphoseek's indications beyond breast and cancer and melanoma and into head and neck cancers as well. With a big push expected in utilizing diagnostics to personalize treatment options for cancer patients over the next decade, I could certainly see Navidea becoming a success.

APPY Get in before this takes off. Here's the reason:

1. Price 2.39
2. Float 20.61 mil
3. Not noticed yet
4. Chart looks great!
5. Developed a kit called APPY1 which has already been approved in Europe. Already being sold during the past year. The kit is to detect appendicitis by a simple blood test for hospitals. Cuts out the need for MRI's and cat scans for anyone coming in complaining of serious abdominal pain. Especially kids.
6. 4 major catalysts that are going to launch this low floater to the moon by the end of March.

a) Patient enrollment in the US for their final Phase 3 trial(Any day now)!
b)Topline data from their Phase 3 trial by end of March
c)Financials by end of March which will report the sales of the already approved APPY1 kit in Europe
d) 510 device application to the FDA end of March after Phase 3 results for a June decision date by the FDA.

If the kit has been approved in Europe and is being sold, ask yourself what the likelihood of good phase 3 results will be in the US. Look at the chart and see for yourself! This is being targeted by analysts at $5-7 by the summer. Thought I would just give a heads up to anyone looking for an early entry on a super low floater! ~GL

5+ bagger easy next press release... Here's why, my wife is management at the Marriot. I like to play pinkies here and there but ones with great potential. I stumbled on OTHM had her do a little research. They are trying to capture some market in vacation destinations. Potential looks promising, and company is real which is a big deal.... ! Just to show you I am not some penny pumper, this is what just happened to me today with CPRX... I hold 193,000 shares... it's been a good day, and I wish the best of luck to everyone holding OTHM.. don't have time to be writing all day, but if someone does, maybe spread the word on some of the top forums... this is going to go, trust me.. GL

ChrisP Member Profile ChrisP Friday, August 23, 2013 11:04:08 AM
Re: None Post # of 1913

Top Line Results for Tourette's
I wanted to forward this email I received last night from IR. Personally, I am holding for top line Phase 3, but sounds like we may get a nice shock and awe press release anytime after OCT which will start a run up I am sure. Forward this over to $heff's site if anyone is a premium member. GL

Dear Mr. xxxxxxxxxxxx,



I spoke with the Catalyst regarding your question. The company has contacted Mt. Sinai to assess the status of the trial. Catalyst plans to provide a public update as soon as it receives a confirmation from Mt. Sinai. Since the Tourette’s study is not material to the company at this point management did not include the status in the 10-Q. I hope that helps. Please feel free to contact me again with any questions. You can also reach me by phone at 917-322-2571.



Sincerely,



Melody



_________________________

Melody A. Carey/Co-President

Rx Communications Group, LLC

445 Park Avenue, 10th Floor, New York, NY 10022/Office: 917-322-2571



Rx Communications Group, LLC: Providing award-winning communications counsel to life sciences and health care service companies since 2000



From: xxxxxxxxxxxxxxxxxxxxxxxxx
Sent: Sunday, August 18, 2013 12:00 AM
To: mcarey@rxir.com
Subject: Top Line Results for Tourette's Disorder study



Dear Ms. Carey,



I am writing requesting some clarification of your company's recent 10-Q vs. your share holder's presentation dated June 2013. In the presentation from June, it is stated that there would be top-line results for Tourette's Disorder released in Q4 2013. In the 10-Q there is no mention of top line results being released for Tourette's. Could you please give me some clarification to this matter. I am a current share holder of 193,000 shares.



Thank you for your time.



Regards,

xxxxxxxxxxxxxx

I agree, possible 5+ bagger within days!

Congrats to everyone here.... :) Funny, wonder if IR knew about this news.... :D Too bad they can't slip this kind of news ahead of time once in awhile huh...!

Next press release is going to make this soar above .005+ in an instant. They are getting very close to project completion and financing... chart looks fantastic!

Top Line Results for Tourette's
I wanted to forward this email I received last night from IR. Personally, I am holding for top line Phase 3, but sounds like we may get a nice shock and awe press release anytime after OCT which will start a run up I am sure. Forward this over to $heff's site if anyone is a premium member. GL

Dear Mr. xxxxxxxxxxxx,



I spoke with the Catalyst regarding your question. The company has contacted Mt. Sinai to assess the status of the trial. Catalyst plans to provide a public update as soon as it receives a confirmation from Mt. Sinai. Since the Tourette’s study is not material to the company at this point management did not include the status in the 10-Q. I hope that helps. Please feel free to contact me again with any questions. You can also reach me by phone at 917-322-2571.



Sincerely,



Melody



_________________________

Melody A. Carey/Co-President

Rx Communications Group, LLC

445 Park Avenue, 10th Floor, New York, NY 10022/Office: 917-322-2571



Rx Communications Group, LLC: Providing award-winning communications counsel to life sciences and health care service companies since 2000



From: xxxxxxxxxxxxxxxxxxxxxxxxx
Sent: Sunday, August 18, 2013 12:00 AM
To: mcarey@rxir.com
Subject: Top Line Results for Tourette's Disorder study



Dear Ms. Carey,



I am writing requesting some clarification of your company's recent 10-Q vs. your share holder's presentation dated June 2013. In the presentation from June, it is stated that there would be top-line results for Tourette's Disorder released in Q4 2013. In the 10-Q there is no mention of top line results being released for Tourette's. Could you please give me some clarification to this matter. I am a current share holder of 193,000 shares.



Thank you for your time.



Regards,

xxxxxxxxxxxxxx

OTHM.002 Huge news... on it's next leg up .005+ by days end easy!

OTHM .002 news out and moving fast! Just got 10 mil in financing high of the year .03... next 10+ bagger easy! Chart insane.

DCTH .38 anyone checking this one out? Financials out Aug 8th, with possible catalyst news on their FDA decision date on Sept 13th... it's been beat down since May from their 1.60 range from less favorable news from FDA review panel, but that doesn't mean they won't get approval... I think this is the ground floor for a real nice bounce!
http://stockcharts.com/h-sc/ui?s=DCTH

Here is another update...

http://community.nasdaq.com/News/2012-09/smith-electric-vehicles-withdraws-76-million-us-ipo.aspx?storyid=175296

MRGE bounce time with plenty more to come imo.

MRGE looking good at these levels. Missed their numbers by a little which caused a sell off, but look what happened right after financials were announced on the 8th and the stock tanked...

http://openinsider.com/search?q=mrge

look at this potential bounce oversold stock with big insider buying...

http://stockcharts.com/h-sc/ui?s=MRGE

NVTLmoves on very low volume. Float is low at 28m and 74% institutional...

http://stockcharts.com/h-sc/ui?s=NVTL

Good buy at these prices IMO.

NVTL I also like the fact that the float is only 27.9 M and 74% of that is held by institutions..

[http://finance.yahoo.com/q/mh?s=NVTL+Major+Holders

Also some recent insider buying after the financials, I am expecting a nice bounce soon..

/b]http://openinsider.com/search?q=nvtl

Going to pull an easy 25% from this bounce!

ALXA .60 potential explosive runner in the near term. Just based on the chart alone, it is ready for a pop.

http://stockcharts.com/h-sc/ui?s=ALXA


It has two major catalysts.
1. It has a FDA decision date of May 4th for it's inhaled antipsychotic drug Adasuve (Staccato Loxipine). Loxapine is already available in the US, this would be an inhaled version.

http://finance.yahoo.com/news/Alexza-Announces-Extension-prnews-391788033.html?x=0

2. They have a partner Grupo Ferrer that will distribute the drug in Europe, Latin America, and Russia and instead of milestone payments to Alexa, they have agreed to purchase 2.42 million common shares of ALXA at a price of 1.24, 100% gain from current levels upon Alexa's request, and another 8 million at a premium instead of future milestone payments.

This has a potential if approved of possibly a 300-400% gain in the next month from these levels IMO.

USU 1.44 Uranium play company, big news on the horizon, over 70% intitutional ownership, 52 week high around $6. This is a no brainer for those looking for an easy 25% from this level. Here's some news that just came out this morning! GL

http://portsmouth-dailytimes.com/bookmark/17581986

http://stockcharts.com/h-sc/ui?s=USU

USU 1.46 Uranium play here. 79% institutional ownership. At bottom IMO. This has plenty of room to run. Uranium market on the rise after a tough year last year from the Japan ordeal.

http://stockcharts.com/freecharts/gallery.html?USU

xco 7.18 Natural Gas play... natural gas took a hit recently due to lack of demmand, but exploratory companies are holding back in drilling 2012, lowering the supply and saving money. XCO is a buyout target. Trading off a 52 week high of $21, with huge insider buying!!! At it's low as of today.. 93% of float held by institutions!!! What!! Two no brainer plays IMO, thought I would pass them along.

http://openinsider.com/search?q=xco

http://stockcharts.com/h-sc/ui?s=XCO

http://www.thestreet.com/_yahoo/story/11420646/1/energy-stock-favorites-of-hedge-fund-managers.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

http://finance.yahoo.com/q/mh?s=XCO+Major+Holders

XCO Just slammed this natural gas/oil play... coming off the 52 week low, 52 week high of $21 and is in the $7's.

70% float institutional owned

Huge recent insider buying

Financials 23 Feb

Here's the chart

http://stockcharts.com/h-sc/ui?s=XCO

Good luck thought I would pass it along.

MVIS Take a look at this one financials next Monday.

http://stockcharts.com/h-sc/ui?s=MVIS

SHOR Looking pretty! Director just bought $500k today, $300k Nov. 23rd... Something coming?

http://stockcharts.com/h-sc/ui?s=SHOR

This time we are going big time, I notice mms like to shake the tree for stop loses, I keep refiguring my trailer, not sure if I even want one on this stock anymore. Imo, this company is getting gobbled up soon, trying not to get emmotional over this one, but it is hard. GL

GLUU this stock is going insane. Major catalyst coming short term, financials on 7 Feb. 50% float institutional owned, articles on possible buy out near $10, analyst targets of $6, but this is a mobile phone gaming company and is becoming a real big player, and I think we all know how the mobile phones sold during Christmas, so big eyes on last quarter financials! Look at this chart... insider buy of almost $2 mil in Dec @ $3.... think he knows something? GLTA

http://stockcharts.com/h-sc/ui?s=GLUU

GLUU So what does everyone think? Major catalyst coming Feb 7 IMO, financials...

http://stockcharts.com/h-sc/ui

Apple is poised to announce iphone sales January 24... IMO, with a GLUU directer buy of 1.86 million dollars worth of stock a couple weeks ago, and GLUU financials coming out a week after Apple announces their huge sales #'s, $3 a share for GLUU is going to be a thing of the past.

http://www.macrumors.com/2012/01/04/apple-to-announce-1q-2012-earnings-and-iphone-4s-sales-numbers-on-january-24/

http://stockcharts.com/h-sc/ui?s=GLUU

Orions MLK Contest Pick - GLUU 3.06

Thank you and you are right, luck has nothing to do with the charting, GLUU insider buy @ 1.86 million was my signal at this price, and I expect the chart to follow in the very near future.

Oh yeah, ready for the ride on this one! Good luck to you!

GLUU Good stuff coming in IMO. We just had a director buy 1.86 million dollars worth direct since the 14th of Dec. That is huge!!! Mobile device game applications company, (Iphones, ipads, etc...), hot sellers this winter, and so were the game applications. We have financials coming on Feb.6th, and they are expected to be incredible.. if they don't get bought out which is another rumor..! check it out.. priced at $3, don't see this lasting long as we approach Feb.

http://stockcharts.com/h-sc/ui?s=GLUU

http://www.forbes.com/sites/dividendchannel/2012/01/10/tuesday-110-insider-buying-report-gluu/?partner=yahootix

http://seekingalpha.com/article/318285-2012-micro-cap-mobile-index?source=yahoo

Been watching and waiting for weeks now, the run has finally arrived! When they anounce the new CEO this thing shoot explode. Background whomever they choose should be impressive. Got a email from the CFO 2 weeks ago. Expected news soon, so this run indicates to me it is coming sooner than later!